Atossa Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-8.5M | $-9.6M | $-10.9M | $-8.7M | $-8.4M | $-6.7M | $-6.3M | $-7.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $815.0K | $722.0K | $503.0K | $784.0K | $796.0K | $563.0K | $774.0K | $749.0K |
| Net Cash from Operating Activities | $-9.6M | $-9.6M | $-10.5M | $-6.0M | $-7.3M | $-6.0M | $-7.1M | $-4.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $0 | $7.0K | $7.0K | $0 | $9.0K | $0 | $10.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $0 | $-7.0K | $-7.0K | $0 | $-9.0K | $0 | $-10.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $4.0M | $0 | $0 | $0 | $0 | $0 | $3.4M | $0 |
| Net Change in Cash | $-5.6M | $-9.6M | $-10.5M | $-6.0M | $-7.3M | $-6.0M | $-3.7M | $-4.8M |
| Free Cash Flow | $-9.6M | $-9.6M | $-10.5M | $-6.0M | $-7.3M | $-6.0M | $-7.1M | $-4.8M |